Encompass Health Corporation Stock price

Equities

EHC

US29261A1007

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 10:23:25 2024-03-28 am EDT 5-day change 1st Jan Change
82.78 USD +6.74% Intraday chart for Encompass Health Corporation +7.30% +24.32%
Sales 2024 * 5.26B Sales 2025 * 5.7B Capitalization 7.78B
Net income 2024 * 396M Net income 2025 * 441M EV / Sales 2024 * 1.95 x
Net Debt 2024 * 2.47B Net Debt 2025 * 2.36B EV / Sales 2025 * 1.78 x
P/E ratio 2024 *
20 x
P/E ratio 2025 *
18.1 x
Employees 23,832
Yield 2024 *
0.77%
Yield 2025 *
0.77%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Encompass Health Corporation Appoints Andrew Baird as Senior Vice President of Public Policy, Legislation and Regulations CI
Transcript : Encompass Health Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Encompass Health Corp. and Piedmont Announce Plans to Build 40-Bed Inpatient Rehabilitation Hospital in Loganville, Georgia CI
Encompass Health Maintains Quarterly Dividend at $0.15 per Share, Payable April 15 to Holders of Record April 1 MT
Encompass Health Corporation Declares Quarterly Cash Dividend, Payable on April 15, 2024 CI
Encompass Health to Build 60-Bed Arizona Rehab Hospital for Severe Injury Recovery MT
Encompass Health Corporation Announces Preliminary Plans to Build a 60-Bed Inpatient Rehabilitation Hospital in Avondale, Arizona CI
UBS Adjusts Encompass Health Price Target to $88 From $84, Maintains Buy Rating MT
Mizuho Raises Price Target on Encompass Health to $82 From $77, Keeps Buy Rating MT
Deutsche Bank Adjusts Encompass Health Price Target to $83 From $77, Maintains Buy Rating MT
Transcript : Encompass Health Corporation, Q4 2023 Earnings Call, Feb 08, 2024
Encompass Health Q4 Adjusted Earnings, Revenue Rise; 2024 Outlook Set MT
Encompass Health Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (EHC) ENCOMPASS HEALTH Reports Q4 EPS $0.95, vs. Street Est of $0.82 MT
Earnings Flash (EHC) ENCOMPASS HEALTH Reports Q4 Revenue $1.25B, vs. Street Est of $1.237B MT
More news
1 day+1.26%
1 week+1.36%
Current month+4.45%
1 month+3.15%
3 months+15.04%
6 months+15.79%
Current year+16.47%
More quotes
1 week
76.11
Extreme 76.11
77.91
1 month
73.68
Extreme 73.68
78.12
Current year
65.99
Extreme 65.99
78.12
1 year
52.56
Extreme 52.56
78.12
3 years
44.33
Extreme 44.33
89.68
5 years
44.33
Extreme 44.33
89.68
10 years
30.26
Extreme 30.26
89.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 92-12-31
Director of Finance/CFO 63 10-05-05
Chief Tech/Sci/R&D Officer 64 -
Members of the board TitleAgeSince
Director/Board Member 69 13-01-24
Director/Board Member 61 19-12-31
Chief Executive Officer 62 92-12-31
More insiders
Date Price Change Volume
24-03-28 82.74 +6.69% 309 785
24-03-27 77.71 +1.26% 444,070
24-03-26 76.74 +0.79% 410,258
24-03-25 76.14 -0.48% 465,270
24-03-22 76.51 -1.02% 689,457

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Encompass Health Corporation is a post-acute healthcare service. The Company manages its operations through its inpatient rehabilitation segment. The Company is the owner and operator of rehabilitation hospitals. The Company operates hospitals in approximately 37 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. The Company operates approximately 156 inpatient rehabilitation hospitals. It provides specialized rehabilitative treatment on an inpatient basis. The Company's inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It also provides rehabilitative care for patients recovering from injury or illness, using advanced technology and treatments to maximize recovery. Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages technologies and advanced therapies and leads to superior outcomes.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
77.71 USD
Average target price
86.8 USD
Spread / Average Target
+11.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Encompass Health Corporation - Nyse